Novartis successfully completed a massive multi-billion-dollar acquisition of Avidity Biosciences, integrating the pioneering biopharmaceutical enterprise to strengthen its late-stage neuroscience pipeline and advance its proprietary xRNA therapeutic strategy. The acquisition provided the Swiss pharmaceutical giant with full access to advanced antibody-oligonucleotide conjugates designed to target rare neuromuscular diseases, while specific early-stage precision cardiology programs were structurally spun out into independent entities.